4.3 Time to onset of TKI associatied cardiovascular adverse
event
The times of cardiac AEs occurrence were shown in Fig 3. Over 70%
patients developed hypertension within 30 days after the first dose of
TKIs treatment. Identical pattern were found in cardiac failure.
However, the proportion of patients who developed cardiac failure within
30 days were higher in patients administered with sorafenib (70.31%)
and regorafenib(75%), compared with lenvatinib (32.14%) and
cabozantinib(46.15%). In the case of atrial fibrillation, most patients
developed atrial fibrillation within 30 days after the first dose of
sorafenib or regorafenib. We also found that the proportion of patients
developed acute coronary syndrome increased after 180 days use of
lenvatinib compared with the first 30 days(64.29% vs 28.57%). The
proportion of patients developed acute myocardial infarction(AMI) within
30 days were higher in patients taking sorafenib(42.86%) when compared
with lenvatinib(13.64%). On the contrary, lenvatinib seemed to induce
cardiac AEs in a longer period, as the proportion of patients developed
acute myocardial infarction were higher in patients taking
lenvatinib(65.15%) when compared with sorafenib(20%) after 180 days
administration.